Interactive stem-cell comparison

Compare the status, cell source, disease scope, access rule, and risk boundary.

The table is a classification tool, not a treatment matcher. A research category does not confirm a current study or personal eligibility.

Status must be verified before disease or price

Established transplantation, an NMPA-approved product, registered research, and an unsupported commercial injection are not interchangeable. Exact cell identity, indication, hospital, protocol, oversight, risks, costs and follow-up must be documented.

PLAIN LANGUAGE

Medical terms in plain language

Hover, focus, or tap an underlined term for a short definition. These definitions do not replace the treating team’s explanation.

Disease-to-evidence search

Describe a disease or treatment question in ordinary words.

This local search finds relevant evidence pages. It does not diagnose, recommend a therapy, assess eligibility, or send your text to an external model.

Disease or treatment words

Try: multiple myeloma BCMA · type 1 diabetes stem cells · anti-ageing injection

Enter at least two characters to search.

15 pathways shown

On a small screen, swipe or use the keyboard to move across all comparison columns.

Pathway	Evidence category		Disease scope	Access boundary	Principal risks	Evidence date	Review source
Autologous haematopoietic stem-cell transplantationHaematopoietic	Established transplant care	The patient’s mobilised peripheral-blood or marrow haematopoietic stem cells	Established disease-specific pathway for selected lymphoma, myeloma, POEMS, amyloidosis and protocol-defined autoimmune settings.	Hospital transplant-team assessment; mobilisation, collection, conditioning, reinfusion and recovery are one episode. Not a general regenerative injection and not suitable for every blood cancer.	Severe infection; cytopenia; organ toxicity; infertility; relapse; secondary malignancy; graft failure or GVHD where applicable	PUMCH programme · reviewed 29 Aug 2026	Review source
Matched allogeneic haematopoietic stem-cell transplantationHaematopoietic	Established transplant care	HLA-matched related or unrelated donor marrow or peripheral-blood graft	Established pathway for selected acute leukaemia, MDS, marrow failure and inherited blood or immune disorders.	Requires donor search and confirmation, conditioning, GVHD prevention, infection support and long-term follow-up. Transplant-centre status does not establish donor availability, bed access or individual benefit.	Severe infection; cytopenia; organ toxicity; infertility; relapse; secondary malignancy; graft failure or GVHD where applicable	NHC restricted-technology rules · 20 Apr 2022	Review source
Haploidentical allogeneic transplantationHaematopoietic	Established transplant care	Partially HLA-matched related-donor haematopoietic graft	An established allogeneic donor strategy used by qualified Chinese transplant programmes for selected indications.	The exact platform, donor-specific antibodies, graft source and GVHD strategy must be named by the hospital. A wider donor pool does not remove graft failure, GVHD, infection or relapse risk.	Severe infection; cytopenia; organ toxicity; infertility; relapse; secondary malignancy; graft failure or GVHD where applicable	PUMCH programme · reviewed 29 Aug 2026	Review source
Unrelated-donor transplantationHaematopoietic	Established transplant care	Registry-sourced unrelated-donor marrow or peripheral-blood graft	A donor route for selected allogeneic-transplant indications when an acceptable unrelated match is identified.	Requires registry search, confirmatory typing, donor work-up, collection, transport and timing coordination. A hospital’s registry-list entry does not prove a suitable donor or current international access.	Severe infection; cytopenia; organ toxicity; infertility; relapse; secondary malignancy; graft failure or GVHD where applicable	China Marrow Donor Program list · 3 Aug 2026	Review source
Cord-blood haematopoietic transplantationHaematopoietic	Established transplant care	Banked allogeneic umbilical-cord-blood haematopoietic stem cells	A graft option for selected paediatric or adult allogeneic indications when an adequate unit and programme are available.	Licensed bank, unit identity, HLA match, cell dose, transport, engraftment plan and backup must be verified. Cord-blood banking is not proof that a specific unit or transplant is suitable.	Delayed engraftment; severe infection; graft failure; GVHD; unit-quality and transport risks	NHC cord-blood-bank framework · reviewed 29 Aug 2026	Review source
Amimestrocel injection (睿铂生)Mesenchymal	China-approved product	Human umbilical-cord-derived mesenchymal stem cells	Conditionally approved for patients aged 14 or older with steroid-refractory acute GVHD with predominant gastrointestinal involvement.	Prescription medicinal product; exact label, hospital supply, dosing, monitoring and post-marketing evidence require confirmation. The approval does not extend to arthritis, diabetes, neurological disease, organ repair, autism, anti-ageing or wellness.	Infusion reactions; infection and immune complications in a high-risk post-transplant population; uncertain long-term risks requiring continued observation	NMPA page · 11 Jun 2025	Review source
Mesenchymal-cell immune and inflammatory researchMesenchymal	Registered or authorised research	Umbilical-cord, marrow, adipose or placenta-derived mesenchymal stromal cells	Research in lupus, Crohn disease, inflammatory disease and GVHD outside the exact approved amimestrocel population.	Only through an exact filed or authorised protocol with named investigator, ethics review and current recruitment confirmation. A shared cell type does not extend one product approval to another disease or preparation.	Infusion reaction; infection; thrombosis; immune effects; variable potency; uncertain durability and long-term safety	China research framework · effective 1 May 2026	Review source
Musculoskeletal and cartilage researchMesenchymal	Registered or authorised research	Mesenchymal stromal cells, cartilage progenitors or tissue-derived cells	Research in knee osteoarthritis, cartilage, bone and tendon repair.	Research only unless a future NMPA product approval establishes an exact indication. Do not claim routine cartilage regeneration, cure, or replacement of indicated surgery.	Infection; inflammatory reaction; ectopic tissue; inconsistent cell identity or potency; uncertain structural benefit	China research framework · reviewed 29 Aug 2026	Review source
Neurological cell-replacement researchPluripotent-derived	Registered or authorised research	Neural stem or precursor cells, MSCs, and hESC/iPSC-derived neural cells	Research in Parkinson disease, spinal-cord injury, ALS, stroke and neurodegenerative disease.	Protocol-specific research; cell identity, delivery procedure, immunosuppression, imaging and long-term surveillance must be named. No China marketing approval for a neurological stem-cell product is asserted.	Tumour or unwanted growth; immune rejection; infection; ectopic tissue; procedure-related neurological injury	China research framework · reviewed 29 Aug 2026	Review source
Retinal, corneal and ophthalmic researchPluripotent-derived	Registered or authorised research	hESC/iPSC-derived retinal pigment epithelium, corneal progenitors or MSCs	Research in macular, retinal and corneal disease.	Research only; exact graft, surgical technique, immunosuppression and vision endpoints require protocol confirmation. Do not promise restored sight or describe research as routine care.	Tumour or unwanted growth; immune rejection; infection; retinal detachment; inappropriate cell migration	China research framework · reviewed 29 Aug 2026	Review source
Cardiac and vascular regeneration researchTissue or organ progenitor	Registered or authorised research	Marrow mononuclear cells, MSCs, peripheral-blood cells or pluripotent-derived cardiac cells	Research in myocardial injury, heart failure and limb ischaemia.	Research only; standard cardiology, revascularisation and heart-failure care remain controlling. No China marketing approval for general heart or vascular regeneration is asserted.	Arrhythmia; microvascular obstruction; immune reaction; infection; unwanted tissue growth; uncertain durability	China research framework · reviewed 29 Aug 2026	Review source
Stem-cell-derived islet researchPluripotent-derived	Registered or authorised research	hESC-, iPSC- or chemically induced pluripotent-stem-cell-derived islet cells	Early research in type 1 diabetes and cell-based insulin replacement.	Research protocol only; immune protection, insulin use, graft monitoring and long-term surveillance remain study-specific. A published single-patient or early study does not establish routine availability or durable benefit.	Hypoglycaemia; immune rejection; immunosuppression toxicity; tumour or unwanted growth; uncertain durability	Peer-reviewed China study · 25 Sep 2024	Review source
Liver, kidney and lung repair researchMesenchymal	Registered or authorised research	Umbilical-cord or marrow MSCs and organ- or tissue-specific progenitor cells	Research in cirrhosis, kidney injury, COPD, pulmonary fibrosis and other organ injury.	Research only; an exact filed or authorised protocol and current recruitment must be identified. No general NMPA approval for organ repair is asserted.	Infection; immune reaction; thrombosis; ectopic tissue; variable cell quality; uncertain organ-function effect	China research framework · reviewed 29 Aug 2026	Review source
Gene-corrected haematopoietic stem-cell researchGene-modified HSC	Registered or authorised research	Autologous gene-modified haematopoietic stem or progenitor cells	Product- and protocol-specific research for selected inherited blood, immune or metabolic disorders.	Research only unless the exact gene-cell product later receives China marketing approval. Do not infer approval from an ethics review, hospital filing, IND or published case.	Conditioning toxicity; insertional or off-target effects; clonal expansion; infection; infertility; unknown late effects	Biomedical-new-technology framework · effective 1 May 2026	Review source
Unproven multi-disease or wellness stem-cell packagesUnspecified	Unsupported commercial use	Unspecified, mixed or inadequately characterised cells; sometimes marketed alongside exosomes or platelet products	Anti-ageing, rejuvenation, beauty, autism, sexual function, fertility, immune boosting, wellness and broad “regeneration” claims.	Not listed as a treatment pathway. HarbourBridge does not refer patients to unsupported paid interventions. No guarantee, testimonial, price promotion, treatment matching or eligibility assessment is permitted.	Contamination; infection; immune reaction; thrombosis; ectopic tissue; tumour growth; organ or visual injury; financial exploitation	NHC rules and ISSCR guidance · reviewed 29 Aug 2026	Review source

Sourced public cases

Individual clinical courses—reported, not promised.

These neutral summaries come from peer-reviewed case reports or provider-owned public reports. They are not testimonials, representative outcomes, comparative evidence, or a treatment recommendation.

Peer-reviewed case report5 Oct 2022

HSCT complication case: chronic hepatitis E

Case context: Very severe aplastic anaemia
Treatment reported: Matched-sibling allogeneic HSCT
Setting: China multi-institution case report
Observed course: Haematological remission was reported by day 22. Chronic hepatitis E later progressed to cirrhosis; six months of ribavirin was followed by viral clearance and improved liver findings.
Safety or complication: The report illustrates serious infection and liver complications during post-transplant immunosuppression.
Reported follow-up: Multi-year course; liver reassessment 461 days after antiviral initiation

Why this cannot be generalisedA complication case supporting surveillance, not a transplant efficacy estimate or a general infection-rate claim.

Open source

Peer-reviewed case report25 Sep 2024

First-in-human stem-cell-derived islet case

Case context: Type 1 diabetes
Treatment reported: Autologous chemically induced pluripotent stem-cell-derived islets in a phase I study
Setting: Tianjin First Central Hospital
Observed course: The peer-reviewed preliminary report described insulin independence from day 75 and study endpoints met at one year.
Safety or complication: No transplant-related abnormality was identified at one-year review in the report.
Reported follow-up: One year

Why this cannot be generalisedOne first-in-human phase I participant; research only, not a marketed treatment or evidence of general safety and durability.

Open source

HarbourBridge did not treat, recruit, interview, or verify these individuals independently and has no relationship implied by inclusion.

STATUS / FIRST

No defensible all-in stem-cell price range

Transplant cost depends on donor and graft route, conditioning, admission, infection, GVHD, intensive care, readmission and follow-up. A product price is not an episode price. Research participants must receive a written statement of study-related costs and injury arrangements; the applicable Chinese research rules prohibit charging participants research-related fees.

Open the stem-cell guide Find evidenced transplant centres